glauben calyritter ; )
Business Wire würde so etwas nicht veröffentlichen wenn es keine Fakten hätte....
|
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
Re: Oh J..... by: bruzzones2000 (53/California) Long-Term Sentiment: Strong Buy | 06/21/06 01:59 pm Msg: 28187 of 28189 |
How silly. Had you bought this stock last week at .18, you would have seen an almost twenty percent return on it by today. While you focus on what "could be" that is negative, you haven't focused on the positives. The first positives were the approvals from Kenya and South Africa. Had you paid attention to the potential and opportunities in those countries, you would have seen, via the many posts made regarding the gravity of the situation there: 1. Calypte has the highest quality oral test on the market. 2. It was established and approved over the counter in the Middle East in January. 3. It has been used by the CDC and the company is a partner with the CDC with another product. 4. The market needed a effectively priced, rapid oral test that the African people would be receptive to as they fear blood tests. 5. Calypte is priced well under the ONLY competitor, Orasure who sells their tests for $5 a test in developing countries. Calypte announced they intended to sell their test to distributors for $1.68 a test with a .42 to .48 margin. 6. The management of Calypte are global leaders in enormous countries, having founded one of the largest oil companies in the world, telecommunications companies in the world, etc... 7. The CEO, Roger Gale, is one of the most respected business leaders in the UK, Europe and Asia. 8. They are pending approval for their test in China, the largest market in the world. 9. They acquired a production plant in China. 10. They have the contacts and backing of very influential persons. 11. India trials are to be announced in August or September. 12. Pending approval of the product in Russia is expected in September or October. This is a far cry from the little pink sheet company mining for gold in Nevada and who previously had a business plan for "caviar and entertainment" bars in U.S. high rises. It ain't your local donut shop either. The positives far outweigh the negatives...Calypte has and will have no problem with financing. It has and will have no problem with continued listing in my opinion. Its reorganized beautifully. I find your statements hilarious considering the companies you claim to invest within and Calypte and the comparison of their potential. Subj: Re: Oh J..... By: mksdaddy1 Date: 06/21/06 01:45 pm See what your saying, but my intent is to buy and go up not buy and watch the pps flip flop for a while. Again, not committed to the .03c profit. LOL. But you are tempting me to the dark side. Timing is everything. With the neg crap about to befall HIV, this is the kind of news they need to steady the shock and stock. Just trying to get a grasp before buying or saying farewell. |
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
Calypte Biomedical Raises $3.0 Million in Private Placement |
LAKE OSWEGO, Ore., June 23 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) (the "Company"), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market primarily for the detection of antibodies to the human immunodeficiency virus (HIV) announced today that it has entered into Subscription Agreements with two accredited investors who will purchase $3.0 million of Calypte's common stock in a private placement transaction. Under the terms of the Subscription Agreements, the Company will issue 16.7 million shares of its common stock at $0.18 per share. The proceeds of the transaction are expected to be used primarily for general working capital purposes as the Company continues to commercialize its Aware(TM) line of rapid diagnostic tests. Roger Gale, CEO of Calypte, stated, "With this infusion of capital, Calypte continues to move closer to its ultimate goal of manufacturing and delivering cost effective HIV diagnostic tests to those population centers suffering from such high levels of HIV infections. We are realizing a portion of that mission by recent serious product inquiries from humanitarian organizations operating in regions where our products have received clearance for sale and distribution." |
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
97 | Wer wird der ARIVA-Trader 2003? | Happy End | ich_will | 25.04.21 10:38 | ||
3![]() | 153 | Der Calypte-Thread | buran | buran | 25.04.21 01:34 | |
6 | Calypte Biomedical, Deckel gebrochen 250% im Plus! | Börsenfan | buran | 10.06.13 23:36 | ||
1 | Abwarten, ist noch nicht aller Tage Abend | Volli | Volli | 25.10.11 15:49 | ||
2![]() | 49 | Calypte AIDS Studie erfolgreich 400 % WKN: 765254 | schubby1 | Volli | 30.06.11 16:36 |